Abstract
Background: B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) can activate signaling pathways by binding to specific receptors. BR3 (BAFF receptor) shows a unique selectivity for BAFF ligand, while B-cell maturation antigen (BCMA) exhibits a stronger interaction between APRIL-BCMA rather than BAFF-BCMA interaction.
Objective: The combined domains were fused with IgG1 Fc to better understand which domain affects the selective interaction of the receptor with BAFF and APRIL.
Methods: Since BR3 and BCMA both contain cysteine-rich repeat domains (CRD) with DxL motif, the binding domains of BR3 and BCMA were segmented into two parts in this study. BR3-1 (CFDLLVRHGVAC) and BCMA-1 (YFDSLLHACIPC) contained the conservative DxL motif, while BR3-2 (GLLRTPRPKPA) and BCMA-2 (QLRCSSNTPPLT) were adjacent to the CRDs yet still joined with BR3-1 and BCMA-1. Affinity between all possible combinations was then tested.
Results: The affinity of BR3-1-BCMA-2-Fc and BR3-1-BR3-2-Fc for BAFF was higher than BCMA-1-BR3-2-Fc and BCMA-1-BCMA-2-Fc. Moreover, BR3-1-BCMA-2-Fc and BCMA-1-BCMA- 2-Fc had affinity for APRIL, while BR3-1-BR3-2-Fc and BCMA-1-BR3-2-Fc hardly interacted with APRIL.
Conclusion: BR3-1 region played a key role for interaction with BAFF, while BCMA-1 region exhibited weaker binding with BAFF. BCMA-2 region having an α-helix might contribute towards selectivity of APRIL-BCMA binding and BR3-2 rigid region had deleterious effects on the APRIL-BR3 interaction. These results provide comprehensive insights of the mechanism of selective interactions, and may promote specific antagonist design in the future.
Keywords: BAFF, APRIL, BR3, BCMA, selective binding, mechanism.
Graphical Abstract
[1]
Mackay, F.; Schneider, P.; Rennert, P.; Browning, J. BAFF AND APRIL: A tutorial on B cell survival. Annu. Rev. Immunol., 2003, 21, 231-264.[http://dx.doi.org/10.1146/annurev.immunol.21.120601.141152] [PMID: 12427767]
[2]
Mackay, F.; Ambrose, C. The TNF family members BAFF and APRIL: The growing complexity. Cytokine Growth Factor Rev., 2003, 14(3-4), 311-324.[http://dx.doi.org/10.1016/S1359-6101(03)00023-6] [PMID: 12787568]
[3]
Schneider, P.; MacKay, F.; Steiner, V.; Hofmann, K.; Bodmer, J.L.; Holler, N.; Ambrose, C.; Lawton, P.; Bixler, S.; Acha-Orbea, H.; Valmori, D.; Romero, P.; Werner-Favre, C.; Zubler, R.H.; Browning, J.L.; Tschopp, J. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J. Exp. Med., 1999, 189(11), 1747-1756.[http://dx.doi.org/10.1084/jem.189.11.1747] [PMID: 10359578]
[4]
Bodmer, J.L.; Schneider, P.; Tschopp, J. The molecular architecture of the TNF superfamily. Trends Biochem. Sci., 2002, 27(1), 19-26.[http://dx.doi.org/10.1016/S0968-0004(01)01995-8] [PMID: 11796220]
[5]
Daridon, C.; Youinou, P.; Pers, J.O. BAFF, APRIL, TWE-PRIL: who’s who? Autoimmun. Rev., 2008, 7(4), 267-271.[http://dx.doi.org/10.1016/j.autrev.2007.05.002] [PMID: 18295728]
[6]
Craxton, A.; Magaletti, D.; Ryan, E.J.; Clark, E.A. Macrophage- and dendritic cell-dependent regulation of human B-cell proliferation requires the TNF family ligand BAFF. Blood, 2003, 101(11), 4464-4471.[http://dx.doi.org/10.1182/blood-2002-10-3123] [PMID: 12531790]
[7]
Karpusas, M.; Cachero, T.G.; Qian, F.; Boriack-Sjodin, A.; Mullen, C.; Strauch, K.; Hsu, Y.M.; Kalled, S.L. Crystal structure of extracellular human BAFF, a TNF family member that stimulates B lymphocytes. J. Mol. Biol., 2002, 315(5), 1145-1154.[http://dx.doi.org/10.1006/jmbi.2001.5296] [PMID: 11827482]
[8]
Rolink, A.G.; Tschopp, J.; Schneider, P.; Melchers, F. BAFF is a survival and maturation factor for mouse B cells. Eur. J. Immunol., 2002, 32(7), 2004-2010.[http://dx.doi.org/10.1002/1521-4141(200207)32:7<2004::AID-IMMU2004>3.0.CO;2-5] [PMID: 12115621]
[9]
Shulga-Morskaya, S.; Dobles, M.; Walsh, M.E.; Ng, L.G.; MacKay, F.; Rao, S.P.; Kalled, S.L.; Scott, M.L. B cell-activating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation. J. Immunol., 2004, 173(4), 2331-2341.[http://dx.doi.org/10.4049/jimmunol.173.4.2331] [PMID: 15294946]
[10]
Ng, L.G.; Mackay, C.R.; Mackay, F. The BAFF/APRIL system: Life beyond B lymphocytes. Mol. Immunol., 2005, 42(7), 763-772.[http://dx.doi.org/10.1016/j.molimm.2004.06.041] [PMID: 15829264]
[11]
Gardam, S.; Brink, R. Non-Canonical NF-κB Signaling Initiated by BAFF Influences B Cell Biology at Multiple Junctures. Front. Immunol., 2014, 4, 509.[http://dx.doi.org/10.3389/fimmu.2013.00509] [PMID: 24432023]
[12]
Hahne, M.; Kataoka, T.; Schröter, M.; Hofmann, K.; Irmler, M.; Bodmer, J.L.; Schneider, P.; Bornand, T.; Holler, N.; French, L.E.; Sordat, B.; Rimoldi, D.; Tschopp, J. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J. Exp. Med., 1998, 188(6), 1185-1190.[http://dx.doi.org/10.1084/jem.188.6.1185] [PMID: 9743536]
[13]
Roth, W.; Wagenknecht, B.; Klumpp, A.; Naumann, U.; Hahne, M.; Tschopp, J.; Weller, M. APRIL, a new member of the tumor necrosis factor family, modulates death ligand-induced apoptosis. Cell Death Differ., 2001, 8(4), 403-410.[http://dx.doi.org/10.1038/sj.cdd.4400827] [PMID: 11550092]
[14]
Mackay, F.; Tangye, S.G. The role of the BAFF/APRIL system in B cell homeostasis and lymphoid cancers. Curr. Opin. Pharmacol., 2004, 4(4), 347-354.[http://dx.doi.org/10.1016/j.coph.2004.02.009] [PMID: 15251127]
[15]
López-Fraga, M.; Fernández, R.; Albar, J.P.; Hahne, M. Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase. EMBO Rep., 2001, 2(10), 945-951.[http://dx.doi.org/10.1093/embo-reports/kve198] [PMID: 11571266]
[16]
Yu, G.; Boone, T.; Delaney, J.; Hawkins, N.; Kelley, M.; Ramakrishnan, M.; McCabe, S.; Qiu, W.R.; Kornuc, M.; Xia, X.Z.; Guo, J.; Stolina, M.; Boyle, W.J.; Sarosi, I.; Hsu, H.; Senaldi, G.; Theill, L.E. APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity. Nat. Immunol., 2000, 1(3), 252-256.[http://dx.doi.org/10.1038/79802] [PMID: 10973284]
[17]
Mackay, F.; Schneider, P. Cracking the BAFF code. Nat. Rev. Immunol., 2009, 9(7), 491-502.[http://dx.doi.org/10.1038/nri2572] [PMID: 19521398]
[18]
Dickinson, G.S.; Sun, G.; Bram, R.J.; Alugupalli, K.R.; Efficient, B. Efficient B cell responses to Borrelia hermsii infection depend on BAFF and BAFFR but not TACI. Infect. Immun., 2014, 82(1), 453-459.[http://dx.doi.org/10.1128/IAI.01147-13] [PMID: 24218480]
[19]
Mackay, F.; Silveira, P.A.; Brink, R. B cells and the BAFF/APRIL axis: Fast-forward on autoimmunity and signaling. Curr. Opin. Immunol., 2007, 19(3), 327-336.[http://dx.doi.org/10.1016/j.coi.2007.04.008] [PMID: 17433868]
[20]
Schiemann, B.; Gommerman, J.L.; Vora, K.; Cachero, T.G.; Shulga-Morskaya, S.; Dobles, M.; Frew, E.; Scott, M.L. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science, 2001, 293(5537), 2111-2114.[http://dx.doi.org/10.1126/science.1061964] [PMID: 11509691]
[21]
Hayden, M.S.; Ghosh, S. Shared principles in NF-kappaB signaling. Cell, 2008, 132(3), 344-362.[http://dx.doi.org/10.1016/j.cell.2008.01.020] [PMID: 18267068]
[22]
Cheng, Y.; Yan, S.; Zhao, W.; Huang, Q.; Lian, L.; Wei, W. The effect of BLyS on the activity of peripheral B lymphocytes mediated by BLyS receptors in patients with systemic lupus erythematosus. Scand. J. Clin. Lab. Invest., 2013, 73(2), 141-147.[http://dx.doi.org/10.3109/00365513.2012.756120] [PMID: 23336587]
[23]
Vincent, F.B.; Morand, E.F.; Schneider, P.; Mackay, F. The BAFF/APRIL system in SLE pathogenesis. Nat. Rev. Rheumatol., 2014, 10(6), 365-373.[http://dx.doi.org/10.1038/nrrheum.2014.33] [PMID: 24614588]
[24]
Wei, F.; Chang, Y.; Wei, W. The role of BAFF in the progression of rheumatoid arthritis. Cytokine, 2015, 76(2), 537-544.[http://dx.doi.org/10.1016/j.cyto.2015.07.014] [PMID: 26198030]
[25]
Vincent, F.B.; Saulep-Easton, D.; Figgett, W.A.; Fairfax, K.A.; Mackay, F. The BAFF/APRIL system: Emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev., 2013, 24(3), 203-215.[http://dx.doi.org/10.1016/j.cytogfr.2013.04.003] [PMID: 23684423]
[26]
Thompson, N.; Isenberg, D.A.; Jury, E.C.; Ciurtin, C. Exploring BAFF: its expression, receptors and contribution to the immunopathogenesis of Sjögren’s syndrome. Rheumatology (Oxford), 2016, 55(9), 1548-1555.[http://dx.doi.org/10.1093/rheumatology/kev420] [PMID: 26790457]
[27]
Hymowitz, S.G.; Patel, D.R.; Wallweber, H.J.; Runyon, S.; Yan, M.; Yin, J.; Shriver, S.K.; Gordon, N.C.; Pan, B.; Skelton, N.J.; Kelley, R.F.; Starovasnik, M.A. Structures of APRIL-receptor complexes: like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding. J. Biol. Chem., 2005, 280(8), 7218-7227.[http://dx.doi.org/10.1074/jbc.M411714200] [PMID: 15542592]
[28]
Gross, J.A.; Johnston, J.; Mudri, S.; Enselman, R.; Dillon, S.R.; Madden, K.; Xu, W.; Parrish-Novak, J.; Foster, D.; Lofton-Day, C.; Moore, M.; Littau, A.; Grossman, A.; Haugen, H.; Foley, K.; Blumberg, H.; Harrison, K.; Kindsvogel, W.; Clegg, C.H. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature, 2000, 404(6781), 995-999.[http://dx.doi.org/10.1038/35010115] [PMID: 10801128]
[29]
Bossen, C.; Schneider, P. BAFF, APRIL and their receptors: structure, function and signaling. Semin. Immunol., 2006, 18(5), 263-275.[http://dx.doi.org/10.1016/j.smim.2006.04.006] [PMID: 16914324]
[30]
Schuepbach-Mallepell, S.; Das, D.; Willen, L.; Vigolo, M.; Tardivel, A.; Lebon, L.; Kowalczyk-Quintas, C.; Nys, J.; Smulski, C.; Zheng, T.S.; Maskos, K.; Lammens, A.; Jiang, X.; Hess, H.; Tan, S.L.; Schneider, P. Stoichiometry of heteromeric BAFF and APRIL cytokines dictates their receptor binding and signaling properties. J. Biol. Chem., 2015, 290(26), 16330-16342.[http://dx.doi.org/10.1074/jbc.M115.661405] [PMID: 25953898]
[31]
Thompson, J.S.; Bixler, S.A.; Qian, F.; Vora, K.; Scott, M.L.; Cachero, T.G.; Hession, C.; Schneider, P.; Sizing, I.D.; Mullen, C.; Strauch, K.; Zafari, M.; Benjamin, C.D.; Tschopp, J.; Browning, J.L.; Ambrose, C. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science, 2001, 293(5537), 2108-2111.[http://dx.doi.org/10.1126/science.1061965] [PMID: 11509692]
[32]
Yan, M.; Brady, J.R.; Chan, B.; Lee, W.P.; Hsu, B.; Harless, S.; Cancro, M.; Grewal, I.S.; Dixit, V.M. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr. Biol., 2001, 11(19), 1547-1552.[http://dx.doi.org/10.1016/S0960-9822(01)00481-X] [PMID: 11591325]
[33]
Smulski, C.R.; Kury, P.; Seidel, L.M.; Staiger, H.S.; Edinger, A.K.; Willen, L.; Seidl, M.; Hess, H.; Salzer, U.; Rolink, A.G.; Rizzi, M.; Schneider, P.; Eibel, H. BAFF- and TACI-Dependent Processing of BAFFR by ADAM Proteases Regulates the Survival of B Cells. Cell Rep., 2017, 18(9), 2189-2202.[http://dx.doi.org/10.1016/j.celrep.2017.02.005] [PMID: 28249164]
[34]
O’Connor, B.P.; Raman, V.S.; Erickson, L.D.; Cook, W.J.; Weaver, L.K.; Ahonen, C.; Lin, L.L.; Mantchev, G.T.; Bram, R.J.; Noelle, R.J. BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med., 2004, 199(1), 91-98.[http://dx.doi.org/10.1084/jem.20031330] [PMID: 14707116]
[35]
Ng, L.G.; Sutherland, A.P.R.; Newton, R.; Qian, F.; Cachero, T.G.; Scott, M.L.; Thompson, J.S.; Wheway, J.; Chtanova, T.; Groom, J.; Sutton, I.J.; Xin, C.; Tangye, S.G.; Kalled, S.L.; Mackay, F.; Mackay, C.R. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J. Immunol., 2004, 173(2), 807-817.[http://dx.doi.org/10.4049/jimmunol.173.2.807] [PMID: 15240667]
[36]
Fu, L.; Lin-Lee, Y.C.; Pham, L.V.; Tamayo, A.T.; Yoshimura, L.C.; Ford, R.J. BAFF-R promotes cell proliferation and survival through interaction with IKKbeta and NF-kappaB/c-Rel in the nucleus of normal and neoplastic B-lymphoid cells. Blood, 2009, 113(19), 4627-4636.[http://dx.doi.org/10.1182/blood-2008-10-183467] [PMID: 19258594]
[37]
Yang, S.; Li, J.Y.; Xu, W. Role of BAFF/BAFF-R axis in B-cell non-Hodgkin lymphoma. Crit. Rev. Oncol. Hematol., 2014, 91(2), 113-122.[http://dx.doi.org/10.1016/j.critrevonc.2014.02.004] [PMID: 24629840]
[38]
Peperzak, V.; Vikstrom, I.; Walker, J.; Glaser, S.P.; LePage, M.; Coquery, C.M.; Erickson, L.D.; Fairfax, K.; Mackay, F.; Strasser, A.; Nutt, S.L.; Tarlinton, D.M. Mcl-1 is essential for the survival of plasma cells (vol 14, pg 290, 2013). Nat. Immunol., 2013, 14(8), 877-877.[http://dx.doi.org/10.1038/ni0813-877c]
[39]
Laurent, S.A.; Hoffmann, F.S.; Kuhn, P.H.; Cheng, Q.; Chu, Y.; Schmidt-Supprian, M.; Hauck, S.M.; Schuh, E.; Krumbholz, M.; Rübsamen, H.; Wanngren, J.; Khademi, M.; Olsson, T.; Alexander, T.; Hiepe, F.; Pfister, H.W.; Weber, F.; Jenne, D.; Wekerle, H.; Hohlfeld, R.; Lichtenthaler, S.F.; Meinl, E. γ-Secretase directly sheds the survival receptor BCMA from plasma cells. Nat. Commun., 2015, 6, 7333.[http://dx.doi.org/10.1038/ncomms8333] [PMID: 26065893]
[40]
Bu, D.X.; Singh, R.; Choi, E.E.; Ruella, M.; Nunez-Cruz, S.; Mansfield, K.G.; Bennett, P.; Barton, N.; Wu, Q.; Zhang, J.; Wang, Y.; Wei, L.; Cogan, S.; Ezell, T.; Joshi, S.; Latimer, K.J.; Granda, B.; Tschantz, W.R.; Young, R.M.; Huet, H.A.; Richardson, C.J.; Milone, M.C. Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma. Oncotarget, 2018, 9(40), 25764-25780.[http://dx.doi.org/10.18632/oncotarget.25359] [PMID: 29899820]
[41]
Avery, D.T.; Kalled, S.L.; Ellyard, J.I.; Ambrose, C.; Bixler, S.A.; Thien, M.; Brink, R.; Mackay, F.; Hodgkin, P.D.; Tangye, S.G. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J. Clin. Invest., 2003, 112(2), 286-297.[http://dx.doi.org/10.1172/JCI18025] [PMID: 12865416]
[42]
Treml, L.S.; Carlesso, G.; Hoek, K.L.; Stadanlick, J.E.; Kambayashi, T.; Bram, R.J.; Cancro, M.P.; Khan, W.N. TLR stimulation modifies BLyS receptor expression in follicular and marginal zone B cells. J. Immunol., 2007, 178(12), 7531-7539.[http://dx.doi.org/10.4049/jimmunol.178.12.7531] [PMID: 17548587]
[43]
Groom, J.R.; Fletcher, C.A.; Walters, S.N.; Grey, S.T.; Watt, S.V.; Sweet, M.J.; Smyth, M.J.; Mackay, C.R.; Mackay, F. BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J. Exp. Med., 2007, 204(8), 1959-1971.[http://dx.doi.org/10.1084/jem.20062567] [PMID: 17664289]
[44]
Figgett, W.A.; Fairfax, K.; Vincent, F.B.; Le Page, M.A.; Katik, I.; Deliyanti, D.; Quah, P.S.; Verma, P.; Grumont, R.; Gerondakis, S.; Hertzog, P.; O’Reilly, L.A.; Strasser, A.; Mackay, F. The TACI receptor regulates T-cell-independent marginal zone B cell responses through innate activation-induced cell death. Immunity, 2013, 39(3), 573-583.[http://dx.doi.org/10.1016/j.immuni.2013.05.019] [PMID: 24012421]
[45]
Zhao, L.D.; Li, Y.; Smith, M.F., Jr; Wang, J.S.; Zhang, W.; Tang, F.L.; Tian, X.P.; Wang, H.Y.; Zhang, F.C.; Ba, D.N.; He, W.; Zhang, X. Expressions of BAFF/BAFF receptors and their correlation with disease activity in Chinese SLE patients. Lupus, 2010, 19(13), 1534-1549.[http://dx.doi.org/10.1177/0961203310375268] [PMID: 20974656]
[46]
Mantchev, G.T.; Cortesão, C.S.; Rebrovich, M.; Cascalho, M.; Bram, R.J. TACI is required for efficient plasma cell differentiation in response to T-independent type 2 antigens. J. Immunol., 2007, 179(4), 2282-2288.[http://dx.doi.org/10.4049/jimmunol.179.4.2282] [PMID: 17675489]
[47]
Figgett, W.A.; Deliyanti, D.; Fairfax, K.A.; Quah, P.S.; Wilkinson-Berka, J.L.; Mackay, F. Deleting the BAFF receptor TACI protects against systemic lupus erythematosus without extensive reduction of B cell numbers. J. Autoimmun., 2015, 61, 9-16.[http://dx.doi.org/10.1016/j.jaut.2015.04.007] [PMID: 26027434]
[48]
Bossen, C.; Cachero, T.G.; Tardivel, A.; Ingold, K.; Willen, L.; Dobles, M.; Scott, M.L.; Maquelin, A.; Belnoue, E.; Siegrist, C.A.; Chevrier, S.; Acha-Orbea, H.; Leung, H.; Mackay, F.; Tschopp, J.; Schneider, P. TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood, 2008, 111(3), 1004-1012.[http://dx.doi.org/10.1182/blood-2007-09-110874] [PMID: 17942754]
[49]
Mackay, F.; Schneider, P. TACI, an enigmatic BAFF/APRIL receptor, with new unappreciated biochemical and biological properties. Cytokine Growth Factor Rev., 2008, 19(3-4), 263-276.[http://dx.doi.org/10.1016/j.cytogfr.2008.04.006] [PMID: 18514565]
[50]
Kim, H.M.; Yu, K.S.; Lee, M.E.; Shin, D.R.; Kim, Y.S.; Paik, S.G.; Yoo, O.J.; Lee, H.; Lee, J.O. Crystal structure of the BAFF-BAFF-R complex and its implications for receptor activation. Nat. Struct. Biol., 2003, 10(5), 342-348.[http://dx.doi.org/10.1038/nsb925] [PMID: 12715002]
[51]
Starling, G.C.; Kiener, P.A.; Aruffo, A.; Bajorath, J. Analysis of the ligand binding site in Fas (CD95) by site-directed mutagenesis and comparison with TNFR and CD40. Biochemistry, 1998, 37(11), 3723-3726.[http://dx.doi.org/10.1021/bi972959d] [PMID: 9521690]
[52]
Obmolova, G.; Teplyakov, A.; Malia, T.J.; Wunderler, N.; Kwok, D.; Barone, L.; Sweet, R.; Ort, T.; Scully, M.; Gilliland, G.L. Epitope-dependent mechanisms of CD27 neutralization revealed by X-ray crystallography. Mol. Immunol., 2017, 83, 92-99.[http://dx.doi.org/10.1016/j.molimm.2017.01.005] [PMID: 28119207]
[53]
Mukai, Y.; Shibata, H.; Nakamura, T.; Yoshioka, Y.; Abe, Y.; Nomura, T.; Taniai, M.; Ohta, T.; Ikemizu, S.; Nakagawa, S.; Tsunoda, S.; Kamada, H.; Yamagata, Y.; Tsutsumi, Y. Structure-function relationship of tumor necrosis factor (TNF) and its receptor interaction based on 3D structural analysis of a fully active TNFR1-selective TNF mutant. J. Mol. Biol., 2009, 385(4), 1221-1229.[http://dx.doi.org/10.1016/j.jmb.2008.11.053] [PMID: 19084540]
[54]
Byla, P.; Andersen, M.H.; Holtet, T.L.; Jacobsen, H.; Munch, M.; Gad, H.H.; Thøgersen, H.C.; Hartmann, R. Selection of a novel and highly specific tumor necrosis factor alpha (TNFalpha) antagonist: insight from the crystal structure of the antagonist-TNFalpha complex. J. Biol. Chem., 2010, 285(16), 12096-12100.[http://dx.doi.org/10.1074/jbc.M109.063305] [PMID: 20179326]
[55]
Day, E.S.; Cachero, T.G.; Qian, F.; Sun, Y.; Wen, D.; Pelletier, M.; Hsu, Y.M.; Whitty, A. Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA. Biochemistry, 2005, 44(6), 1919-1931.[http://dx.doi.org/10.1021/bi048227k] [PMID: 15697217]
[56]
Liu, Y.; Hong, X.; Kappler, J.; Jiang, L.; Zhang, R.; Xu, L.; Pan, C.H.; Martin, W.E.; Murphy, R.C.; Shu, H.B.; Dai, S.; Zhang, G. Ligand-receptor binding revealed by the TNF family member TALL-1. Nature, 2003, 423(6935), 49-56.[http://dx.doi.org/10.1038/nature01543] [PMID: 12721620]
[57]
Wallweber, H.J.; Compaan, D.M.; Starovasnik, M.A.; Hymowitz, S.G. The crystal structure of a proliferation-inducing ligand, APRIL. J. Mol. Biol., 2004, 343(2), 283-290.[http://dx.doi.org/10.1016/j.jmb.2004.08.040] [PMID: 15451660]
[58]
Wang, H.; Marsters, S.A.; Baker, T.; Chan, B.; Lee, W.P.; Fu, L.; Tumas, D.; Yan, M.; Dixit, V.M.; Ashkenazi, A.; Grewal, I.S. TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat. Immunol., 2001, 2(7), 632-637.[http://dx.doi.org/10.1038/89782] [PMID: 11429548]
[59]
Lenert, A.; Lenert, P. Current and emerging treatment options for ANCA-associated vasculitis: Potential role of belimumab and other BAFF/APRIL targeting agents. Drug Des. Devel. Ther., 2015, 9, 333-347.[http://dx.doi.org/10.2147/DDDT.S67264] [PMID: 25609919]
[60]
Stohl, W.; Hiepe, F.; Latinis, K.M.; Thomas, M.; Scheinberg, M.A.; Clarke, A.; Aranow, C.; Wellborne, F.R.; Abud-Mendoza, C.; Hough, D.R.; Pineda, L.; Migone, T.S.; Zhong, Z.J.; Freimuth, W.W.; Chatham, W.W. BLISS-52 Study Group; BLISS-76 Study Group. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum., 2012, 64(7), 2328-2337.[http://dx.doi.org/10.1002/art.34400] [PMID: 22275291]
[61]
Hahn, B.H. Belimumab for systemic lupus erythematosus. N. Engl. J. Med., 2013, 368(16), 1528-1535.[http://dx.doi.org/10.1056/NEJMct1207259] [PMID: 23594005]
[62]
Halpern, W. G.; Lappin, P.; Zanardi, T.; Cai, W.; Corcoran, M.; Zhong, J.; Baker, K. P. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: Pharmacokinetic, pharmacodynamic, and toxicologic effects. Toxicological sciences : an official journal of the Society of Toxicology., 2006, 91(2), 586-599.
[63]
Furie, R.; Petri, M.; Zamani, O.; Cervera, R.; Wallace, D.J.; Tegzová, D.; Sanchez-Guerrero, J.; Schwarting, A.; Merrill, J.T.; Chatham, W.W.; Stohl, W.; Ginzler, E.M.; Hough, D.R.; Zhong, Z.J.; Freimuth, W.; van Vollenhoven, R.F.; Grp, B-S. BLISS-76 Study Group. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum., 2011, 63(12), 3918-3930.[http://dx.doi.org/10.1002/art.30613] [PMID: 22127708]
[64]
Navarra, S.V.; Guzmán, R.M.; Gallacher, A.E.; Hall, S.; Levy, R.A.; Jimenez, R.E.; Li, E.K.; Thomas, M.; Kim, H.Y.; León, M.G.; Tanasescu, C.; Nasonov, E.; Lan, J.L.; Pineda, L.; Zhong, Z.J.; Freimuth, W.; Petri, M.A. BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet, 2011, 377(9767), 721-731.[http://dx.doi.org/10.1016/S0140-6736(10)61354-2] [PMID: 21296403]
[65]
Manzi, S.; Sánchez-Guerrero, J.; Merrill, J.T.; Furie, R.; Gladman, D.; Navarra, S.V.; Ginzler, E.M.; D’Cruz, D.P.; Doria, A.; Cooper, S.; Zhong, Z.J.; Hough, D.; Freimuth, W.; Petri, M.A. BLISS-52 and BLISS-76 Study Groups. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: Combined results from two phase III trials. Ann. Rheum. Dis., 2012, 71(11), 1833-1838.[http://dx.doi.org/10.1136/annrheumdis-2011-200831] [PMID: 22550315]
[66]
Rovin, B.H.; Dooley, M.A.; Radhakrishnan, J.; Ginzler, E.M.; Forrester, T.D.; Anderson, P.W. The impact of tabalumab on the kidney in systemic lupus erythematosus: Results from two phase 3 randomized, clinical trials. Lupus, 2016, 25(14), 1597-1601.[http://dx.doi.org/10.1177/0961203316650734] [PMID: 27220348]
[67]
Zhao, Y.; Hao, X.; Feng, J.; Shen, B.; Wei, J.; Sun, J. The comparison of BLyS-binding peptides from phage display library and computer-aided design on BLyS-TACI interaction. Int. Immunopharmacol., 2015, 24(2), 219-223.[http://dx.doi.org/10.1016/j.intimp.2014.12.013] [PMID: 25533501]
[68]
Liu, F.; Su, L.; Chen, Z.; Feng, D.; Wei, J.; Sun, J. Construction of small molecular CTLA4 analogs with CD80-binding affinity. Biochem. Biophys. Res. Commun., 2019, 513(3), 694-700.[http://dx.doi.org/10.1016/j.bbrc.2019.04.041] [PMID: 30987824]
[69]
Chenna, R.; Sugawara, H.; Koike, T.; Lopez, R.; Gibson, T.J.; Higgins, D.G.; Thompson, J.D. Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res., 2003, 31(13), 3497-3500.[http://dx.doi.org/10.1093/nar/gkg500] [PMID: 12824352]
[70]
Fiser, A.; Sali, A. Modeller: generation and refinement of homology-based protein structure models. Methods Enzymol., 2003, 374, 461-491.[http://dx.doi.org/10.1016/S0076-6879(03)74020-8] [PMID: 14696385]
[71]
Laskowski, R.A.; MacArthur, M.W.; Moss, D.S.; Thornton, J.M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Cryst., 1993, 26(2), 283-291.[http://dx.doi.org/10.1107/S0021889892009944]
[72]
Ahmed, B.; Ali Ashfaq, U.; Usman Mirza, M. Medicinal plant phytochemicals and their inhibitory activities against pancreatic lipase: molecular docking combined with molecular dynamics simulation approach. Nat. Prod. Res., 2018, 32(10), 1123-1129.[http://dx.doi.org/10.1080/14786419.2017.1320786] [PMID: 28446025]
[73]
Fu, X.; Xuan, L.; Wang, Y.; Wei, J.; Sun, J. Molecular mechanism of the affinity interactions between BAFF and its peptides by molecular simulations. Protein Pept. Lett., 2015, 22(11), 992-999.[http://dx.doi.org/10.2174/0929866522666150824145607] [PMID: 26299997]
[74]
Zheng, C.; Zhang, X.; Zhao, Z.; Hao, X.; Wei, J.; Sun, J. Selective binding BAFF/APRIL by the in and outside conservative region of BCMA. Protein Pept. Lett., 2017, 24(6), 489-494.[http://dx.doi.org/10.2174/0929866524666170301115209] [PMID: 28260502]
[75]
Fu, X.G.; Mao, Z.; Li, S.M.; Guan, Y.Y.; Jian, X.D.; Sun, J.; Wei, J. Molecular mechanism of the selectivity between BAFF/APRIL and their receptors by molecular simulations. Mol. Simul., 2017, 43(8), 590-598.[http://dx.doi.org/10.1080/08927022.2017.1279281]
Related Journals
Current Protein & Peptide Science
Related Books
Frontiers in Protein and Peptide Sciences
Article Metrics
17